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The aim of the present study was to compare the effects of the 4-methylesculetin with those produced by
prednisolone and sulphasalazine and to elucidate the mechanisms involved in its action. Colitis was
induced in rat by instillation of trinitrobenzenesulphonic acid (TNBS). The colon damage was evaluated
using macroscopic, microscopic and biochemical analysis. In addition, in vitro studies were performed to
evaluate cytokine production in cell cultures using the murine macrophage cell line RAW264.7, mouse
splenocytes and the human colonic epithelial cell line Caco-2. 4-Methylesculetin produced a reduction
of the macroscopic damage score and the recovery of the intestinal cytoarchitecture. These effects were
associated with a prevention of the GSH depletion and an inhibition in AP activity. After colitis relapse,
4-methylesculetin improved the colonic inﬂammatory status as evidenced by histological ﬁndings, with
a reduction in apoptosis, as well as biochemically by inhibition of colonic myeloperoxidase, alkaline
phosphatase and metalloproteinase 9 activities. Paired with this inhibitive activity, there was a decrease
in malondialdehyde content and in IL-1b levels. In vitro assays revealed that 4-methylesculetin promoted
an inhibition in IL-1b, IL-8, IL-2 and IFN-c production in cell cultures. In conclusion, 4-methylesculetin
showed similar efﬁcacy to that obtained with either prednisolone or sulphasalazine, both in the acute
phase of colitis as well as following a curative protocol. The intestinal anti-inﬂammatory activity by
4-methylesculetin is likely related to its ability in reduce colonic oxidative stress and inhibit pro-inﬂam-
matory cytokine production.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction Current therapies involve a combination of aminosalicylates, corti-Inﬂammatory bowel disease (IBD) refers to a group of condi-
tions characterised by inﬂammation in the intestinal tract. Crohn’s
disease (CD) and ulcerative colitis (UC) account for the majority of
these conditions [1]. These diseases are characterised by the
uncontrolled response of the intestinal immune system against
the normal enteric microﬂora, leading to abdominal pain and
chronic diarrhoea for most of the patient’s life [2]. The aetiopatho-
genesis of these diseases has not been fully elucidated but is cur-
rently presumed to result from a complex interplay among
genetic, environmental, microbial and immune factors. Patients
with IBD frequently experience relapse, and medical treatments
are not always able to keep patients in remission in the long term.aulista – UNESP, Institute of
of Phytomedicines, Botucatu,
).
er the Elsevier OA license.costeroids and immunosuppressants such as azathioprine, metho-
trexate, cyclosporine and recently monoclonal antibodies against
tumour necrosis factor a (TNF-a). These drugs have shown beneﬁ-
cial effects in the treatment of IBD, but they might impose risk to
the patients, and not all patients respond to these treatments. They
do not represent a cure for these diseases, and dose-dependent
side effects are frequently associated with all of these treatments
[3]. For this reason, research of new agents that combine pharma-
cologic efﬁcacy and the absence of undesirable adverse effects is
critical.
It has been proposed that reactive oxygen species (ROS) are
involved in the development of tissue injury in patients with
IBD. Indeed, the anti-inﬂammatory effects of corticosteroids in
the treatment of IBD have been ascribed, in part, to their ability
to reduce neutrophil inﬁltration, thus ameliorating oxidative
insult [4]. Moreover, sulphasalazine has been suggested to pro-
duce beneﬁcial effects by inhibiting the formation of ROS from
neutrophils [5].
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natural antioxidant compounds in experimental models of rat coli-
tis, including ﬂavonoids like quercitrin [6,7], rutoside [8], morin
[9], diosmin [10], hesperidin [10], isocoumarin [11] and coumarin
derivatives [12,13]. Our preliminary studies showed that esculetin
and 4-methylesculetin treatments prevent colonic damage in-
duced by TNBS in rats [13]. This study showed that the presence
of methyl group at C-4 in the esculetin molecules improves its
antioxidant and intestinal anti-inﬂammatory activity [13]. This
encouraged us to continue research with 4-methylesculetin to elu-
cidate the mechanism of action and to compare its effects with
those produced by prednisolone and sulphasalazine, two of the
main drugs used for the treatment of IBD in humans.2. Materials and methods
2.1. Materials
All chemicals, including 4-methylesculetin, prednisolone and
sulphasalazine were provided by Sigma, unless otherwise stated.
The test substances were dissolved in methylcellulose (1% w/v)
and prepared fresh daily for administration to the animals.2.2. Animals
Male Wistar rats (weighing 180–200 g) obtained from the Cen-
tral Animal House of the São Paulo State University (UNESP), Bot-
ucatu, São Paulo (Brazil), were housed in standard environmental
conditions (21 C, 60–70% humidity) with 12 h light/dark cycles
and air ﬁltration. Animals had free access to water and food (Bio-
base). Experimental protocols met the ‘‘Guidelines of Animal
Experimentation’’ approved by the Commission of Ethics in Animal
Experimentation (Protocol number 042/04-CEEA), Institute of Bio-
sciences, São Paulo State University (UNESP).2.3. Induction of colitis and assessment of the inﬂammatory process
Colitis was induced using the method originally described by
Morris [14]. Brieﬂy, animals were fasted overnight and then anaes-
thetised with halothane. Under anaesthesia, they were adminis-
tered 10 mg of trinitrobenzenesulphonic acid (TNBS) dissolved in
0.25 ml 50% ethanol (v/v) by means of a Teﬂon cannula inserted
8 cm into the anus. During and after TNBS administration, the rats
remained in a head-down position until they recovered from the
anaesthesia. Rats from the non-colitic (normal) group received
0.25 ml of saline instead of TNBS. Two different protocols were
followed.2.3.1. Acute colitis
Rats received 5 mg/kg of 4-methylesculetin, 2 mg/kg of prednis-
olone or 50 mg/kg of sulphasalazine orally at 96, 72, 48, 24 and
2 hours before colitis induction. The dose of 5 mg/Kg of 4-methyle-
sculetin was chosen based in dose-response study previously per-
formed in our laboratory [13]. The drugs were administered by
means of an oesophageal catheter (volume: 5 ml/kg). Two addi-
tional groups were included for reference: a non-colitic group that
received saline intracolonically and the oral vehicle and a colitic
group that received only the ﬁrst dose of TNBS (TNBS-control with-
out relapse) and the vehicle (5 ml/kg methylcellulose) orally. The
animal body weights, the occurrence of diarrhoea (as detected by
perianal fur soiling) and the total food intakes for each group were
recorded daily. Animals from all groups (n = 7) were killed 48 h
after colitis induction with an overdose of halothane.2.3.2. Colitis relapse
In this protocol, colitis was initially induced with 10 mg of TNBS
in 50% ethanol, as described previously. After 14 days, the animals
were given a second dose of 10 mg of TNBS in an attempt to mimic
the common relapses experienced in humans with IBD. The ani-
mals were divided into three groups, which were treated daily
with the same drugs and doses used in acute colitis. The non-colitic
and TNBS-control groups were similar to the acute colitis group.
Treatments started 2 h after the ﬁrst administration of TNBS and
continued until the day before the animals were killed. Animals
from each group were sacriﬁced after 1, 2 or 3 weeks of colitis
induction, whereas all animals from the colitic control group with-
out relapse were sacriﬁced after 3 weeks. The animals were killed
with an overdose of halothane.
The colonic segments were obtained after laparotomy, and the
occurrence of adhesions between the colon and adjacent organs
was noted. The colonic segments were placed on an ice-cold plate,
cleaned of fat and mesentery, and blotted on ﬁlter paper. The colon
was weighed, and its length was measured under a constant load
(2 g). The colon was opened longitudinally and scored for macro-
scopically visible damage on a 0–10 scale by two observers blinded
to the treatments, according to the criteria described by Bell [15].
The colon was subsequently divided longitudinally into different
pieces to be used for the following biochemical assays: myeloper-
oxidase (MPO) activity, alkaline phosphatase (AP) activity, total
glutathione (GSH) content, malondialdehyde content (MDA), ma-
trix metalloproteinase (MMP-9 and MMP-2) activity, and TNF-a
and interleukin 1b (IL-1b) levels.
2.4. Biochemical assays in colonic specimens
2.4.1. Myeloperoxidase (MPO) activity
MPO activity was measured according to the technique de-
scribed by Krawisz [16]. Samples were suspended in 1 ml of
50 mM phosphate buffer incorporating 0.5% hexadecyltrimethy-
lammonium bromide (pH 6.0) and minced with scissors for 15 s
on an ice-cold plate. The resultant suspension was subsequently
diluted to a ﬁnal 1:20 w/v ratio, homogenised for 1 min with an
automatic Heidolph homogeniser, sonicated for 10 s and subjected
to three freeze-thaw cycles. The homogenates were then centri-
fuged at 7000g and 4 C for 10 min, and the supernatants were as-
sayed for MPO activity. The results are expressed as MPO units per
g of wet tissue.
2.4.2. Alkaline phosphatase (AP) activity
AP activity was measured spectrophotometrically using diso-
dium nitrophenyl phosphate (5.5 mM) as a substrate in a 50 mM
glycine buffer with 0.5 mMMgCl2, pH 10.5 [17]. The results are ex-
pressed as mU per mg of protein.
2.4.3. Glutathione (GSH) content
Total GSH content was quantiﬁed with the recycling assay de-
scribed by Anderson [18]. Samples were thawed, minced, diluted
to a concentration of 1:20 (w/v) in ice-cold 5% (w/v) trichloroacetic
acid and homogenised. The homogenates were centrifuged at
7000g for 15 min at 4 C, and the supernatants were used to quan-
tify glutathione content. The results are expressed as nmol per g of
wet tissue.
2.4.4. TNF-a and IL-1b levels
Colonic samples for the determination of TNF-a and IL-1b levels
were weighed, homogenised, minced on an ice-cold plate and sus-
pended in a centrifugation tube with 10 mmol/L sodium phosphate
buffer (pH 7.4) (1:5 w/ v). The tubes were placed in a shaker sub-
mersed in a water bath (37 C) for 20 min and then centrifuged at
9000g for 30 s at 4 C; the supernatants were frozen at -80 C until
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Kit to measure natural and recombinant rat enzyme (R&D Systems,
Inc. USA). The results were expressed as pg per mg of protein.
2.4.5. Production of malondialdehyde (MDA)
Tissue concentrations of MDA were determined as an index of
lipid peroxidation by the methodology described by Zingarelli
[19]. The tissue samples were homogenised in 1.15% KCl solution.
An aliquot (400 ll) of the homogenate was added to a reaction
mixture containing 200 ll of 8.1% sodium dodecyl sulphate
(SDS), 1500 ll of 20% acetic acid (pH 3.5), 1500 ll of 0.8% thiobar-
bituric acid, and 400 ll distilled water. The samples were then
boiled for one hour at 95 C and centrifuged at 3000g for 10 min-
utes. The absorbance of the supernatant was measured by spectro-
photometry at 532 nm and compared to a standard curve obtained
using 1,1,3,3-tetramethoxypropane. The data were expressed as
nmol per g of wet tissue.
2.4.6. Gelatine zymography for MMP-2 and MMP-9
Zymographic analyses were used to evaluate the gelatinolytic
activity of MMP-2 and -9 in colon rats. Frozen samples of rat colons
from all experimental animals were mechanically homogenised in
a solution of 50 mM Tris-HCl, pH 7.5, with 0.25% of triton X-100
and 10 mM CaCl2 portioned for 0.1 ml for every 30 mg of colonic
tissue. Aliquots of 20 lg of protein were subjected to electrophore-
sis under non-reducing conditions in an 8% polyacrylamide gel co-
polymerised with 0.1% gelatine. After electrophoresis, the gels
were washed twice (for 15 min) in a solution of 2.5% Triton X-
100 to remove the sodium dodecyl sulphate (Bio-Rad, CA, USA), fol-
lowed by two washes in a buffer solution of 50 mM Tris–HCl, pH
8.0, for 5 min. Then the gels were incubated overnight in Tris–
HCl buffer containing 5 mM CaCl2 at 37 C. Finally, the gels were
stained with Coomassie Brilliant Blue R-250 [20]. The bands were
analysed in an Image Master VDS 3.0 (Pharmacia Biotech). The val-
ues are expressed as integrated optical densities.
2.5. Histological ﬁndings
Representative whole gut specimens were taken from a region
of the inﬂamed colon corresponding to the segment adjacent to
the gross macroscopic damage and were ﬁxed in 4% buffered form-
aldehyde. Cross-sections were selected and embedded in parafﬁn.
Equivalent colonic segments were also obtained from the non-
colitic group. Full-thickness sections of 6 lm were obtained at
different levels and stained with haematoxylin and eosin. After
staining, images were subjected to analysis and photomicrography
with a Leica microscope utilising Leica Qwin Plus version 3.3 e 3.40
for the evaluation of the histological damage score by methodology
described by Stucchi [21].
The Feulgen reaction technique [22] was also applied to another
histological section to analyse the degree of compaction of the nu-
clear chromatin in epithelial cells of the crypts that indicated the
apoptosis of these cells. The results were expressed as the number
of apoptotic cells divided by the number of total crypts.
2.6. In vitro effects of 4-methylesculetin on cytokine production
2.6.1. Effects on IL-1b production in RAW264.7 cells
The murine macrophage cell line RAW264.7 was obtained from
the Cell Culture Unit of the University of Granada (Granada, Spain)
and cultured in Dulbecco’s modiﬁed Eagle medium (DMEM) sup-
plemented with 10% FBS and 2 mM L-glutamine in a humidiﬁed
5% CO2 atmosphere at 37 C. These cells were seeded onto 24-well
plates at a density of 5  105 cells per well and grown until conﬂu-
ence. Then they were incubated for 30 min with different concen-
trations of 4-methylesculetin (1–100 lM). Afterwards, these cellswere stimulated with LPS (50 pg/ml) for 20 h, and the supernatants
were collected, centrifuged at 10,000g for 5 min, and frozen until
ELISA analysis of IL-1b concentration.
2.6.2. Effects on IL-8 production in Caco-2 cells
The human colon adenocarcinoma cell line Caco-2, obtained
from the Cell Culture Unit of the University of Granada (Granada,
Spain), was used to test the ability of the 4-methylesculetin to in-
hibit the production/release of IL-8. Cells were grown in DMEM
supplemented with 10% FBS and 2 mM L-glutamine in a humidiﬁed
5% CO2 atmosphere at 37 C. Caco-2 cells were seeded onto 24-well
plates at a density of 5  105 cells per well and grown until forma-
tion of a monolayer. Then they were incubated for 30 min with dif-
ferent concentrations of 4-methylesculetin (1–100 lM). After this,
the cells were stimulated with IL-1b (1 ng/ml) for 20 h, and the
supernatants were collected, centrifuged at 10,000g for 5 min,
and frozen until ELISA analysis of IL-8 concentration.
2.6.3. Effects on IFN-c and IL-2 production on mouse splenocytes
Splenocytes were obtained from male 8-week-old Balb/c mice
provided by the Laboratory Animal Service of the University of Gra-
nada (Granada, Spain). After sacriﬁcing the mice with an overdose
of halothane, the spleens were removed and homogenised in
DMEM with 1% penicillin/streptomycin. After centrifugation
(1500g, 5 min), the erythrocytes were lysed with a buffer (NH4Cl
1.7 mol/L, KHCO3 0.12 mol/L, ethylenediamine-tetra-acetic
9 mmol/L) for 30 min at 4 C. Resting cells were counted with a
haemocytometer and cultured to perform proliferation and stimu-
lation assays in culture medium containing DMEM and 10% FBS.
Cells were incubated at 37 C in a humidiﬁed 5% CO2 atmosphere.
These cells were incubated for 1 hour with different concentrations
of 4-methylesculetin (1, 10, 50 or 100 lM). After this time, the cells
were stimulated with concanavalin A (5 lg/ml) for 48 h, and the
supernatants were collected, centrifuged at 10,000g for 5 min
and frozen at 80 C until ELISA analysis of IFN-c and IL-2
concentrations.
2.6.4. Cell viability assays
The viability of the spleen-derived lymphocytes was quantiﬁed
using the WST-1 Reagent (Roche, Germany) following the protocol
previously described [23] and also by viable cell counting by con-
ventional trypan blue staining using a haemocytometer.
Caco-2 and RAW264.7 cell viability was determined by crystal
violet staining. Brieﬂy, the cells were stained with crystal violet
(0.2%) in ethanol for 30 minutes at room temperature. The plates
were then washed 4 times with PBS. The cells were solubilised
with 1% sodium dodecyl sulphate solution for 30 minutes. The cells
were then centrifuged at 3000g for 5 minutes, and dye uptake was
measured at 540 nm using a microplate reader.
2.7. Statistics
All results are expressed as the mean ± S.E.M., and the differ-
ences between means were tested for statistical signiﬁcance using
one-way analysis of variance (ANOVA). Nonparametric data (score)
are expressed as the median (range) and were analysed with the
Kruskal–Wallis test. Differences between proportions were ana-
lysed with the v2 test. Statistical signiﬁcance was set at p < 0.05.
3. Results
3.1. Acute colitis
The administration of TNBS resulted in colonic inﬂammation,
which was associated with a signiﬁcant reduction in body weight
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shown) and was likely related to a reduction in food intake (data
not shown) and the presence of diarrhoea in this group (Table 1).
The macroscopic analysis of the colonic specimens in the colitic
rats revealed the existence of severe necrosis and inﬂammation
of the mucosa, typically extending 5.0 cm along the colon (Table
1). This inﬂammatory process was associated with an increase in
the colonic weight/length ratio. Biochemically, the colonic damage
was characterised by an increase in colonic MPO, AP (Table 2) and
metalloproteinase-9 activities (Fig. 1), as well as in TNF-a, IL-1b
(Fig. 1) and MDA contents (Table 2). Furthermore, signiﬁcant colo-
nic GSH depletion took place in the inﬂamed colon (Table 2). His-
tological assessment of colonic samples from the TNBS control
group revealed severe transmural disruption of the normal archi-
tecture of the colon, with extensive ulceration and inﬂammation
involving all the intestinal layers of the colon, with a median score
of 16.5 (Fig. 2). These samples were also characterised by severe
oedema, interstitial micro-haemorrhages and diffuse leucocyte
inﬁltration, mainly composed of neutrophils and, to a lesser extent,
lymphocytes and histiocytes (Fig. 2).
The compound 4-methylesculetin showed an intestinal
anti-inﬂammatory preventative effect in colitic rats, similar to
the effects obtained with prednisolone and sulphasalazine, as dem-
onstrated by a decrease in the macroscopic damage scores, in the
percentage of diarrhoea and in the incidence of adhesions between
the colon and adjacent organs (Table 1). This beneﬁt was also as-
sessed biochemically by the increase in GSH content and the inhi-
bition in AP activity (Table 2). Additionally, only prednisolone
signiﬁcantly reduced TNF-a levels (Fig. 1). In contrast, 4-methyle-
sculetin and prednisolone reduced the microscopic damage score
in comparison with the non-treated colitic group (Fig. 2). Thus,
the histological studies showed that treatment with 4-methylescu-
letin and prednisolone promoted the recovery the intestinal cyto-
architecture and a reduction in ulceration, oedema, mucus
depletion and in the inﬁltration of inﬂammatory cells in the sub-
mucosal layers (Fig. 2). In addition, 4-methylesculetin also reduced
this inﬁltration into the lamina propria layer (Fig. 2). Finally, the
number of apoptotic epithelial cells increased two-fold in the TNBS
control group compared to the non-colitic group. However, none of
the tested drugs was able to signiﬁcantly reduce the number of
apoptotic epithelial cells (Table 1).3.2. Colitis relapse
The histological evaluation of the colonic damage in the chronic
phase of the TNBS-colitis revealed that the damage was maximal
seven days after TNBS instillation and decreased gradually during
the following two weeks. At this time, the colonic segments still
appeared macroscopically and microscopically ulcerated and in-
ﬂamed (Table 3). The microscopic analysis also revealed leucocyte
migration accompanied by mucus depletion and oedema. The
inﬂammatory process was also demonstrated by a similar progres-Table 1
Effects of 4-methylesculetin (5 mg/Kg), prednisolone (2 mg/Kg) and sulphasalazine (50 mg
adherences and apoptosis in acute TNBS colitis.
Group Macroscopic damage score (0–10)1 Colonic weight (mg/cm
Non-colitic 0a 80.2 ± 12.17a
TNBS-control 8.0 (7–10)b 144.6 ± 14.04b
4-Methylesculetin 6.0 (3–7)c 138.0 ± 22.17bc
Prednisolone 6.0 (1–8)c 138.9 ± 23.98bc
Sulphasalazine 6.0 (3–7)c 132.8 ± 23.52bc
1 Score data are expressed as the median (range).
2 Exclusion extension of lesion, Colonic weight and apoptosis data are expressed as th
3 Diarrhoea and adherence are expressed in percentage. Value without a common letsion of the biochemical inﬂammatory parameters studied (Tables 4
and 5).
The administration of 4-methylesculetin, prednisolone or sul-
phasalazine once the colonic damage had been induced facilitated
the recovery of the inﬂammatory process during the following two
weeks. This was demonstrated both histologically and biochemi-
cally. Thus, at the ﬁrst week, 4-methylesculetin signiﬁcantly
reduced the macroscopic damage score in comparison to the
TNBS-control and apoptosis. These effects were similar to that ob-
served with prednisolone and sulphasalazine treatments (Table 4).
Microscopically, all treatments also reduced leucocyte inﬁltration
and oedema in the mucosa compared with TNBS-control rats.
Biochemically, these beneﬁcial effects were associated with a
signiﬁcant inhibition of MPO, AP and MMP-9 activities (Tables 4
and 5). In addition, 4-methylesculetin and prednisolone also de-
creased the MDA content (Table 4) and IL-1b colonic levels
(Table 5).
Colitis relapse induced by a second dose of TNBS was character-
ised by a reactivation of the colonic inﬂammatory process, and a
signiﬁcant increase in the microscopic and macroscopic damage
score and in the weight/length ratio (Table 3) were observed when
compared to the normal evolution of colonic damage in the ani-
mals that did not receive the second dose of TNBS (TNBS-control
without relapse). Microscopically, the reactivation of the inﬂam-
matory process was characterised by an increase of leucocyte inﬁl-
tration in the lamina propria and mucosa. Thus, these effects were
associated with colonic oxidative damage, which caused a reduc-
tion in the GSH content and an increase in the others biochemical
parameters evaluated in comparison with colitic animals without
relapse (Tables 4 and 5).
After the colitis relapse, the treatment with 4-methylesculetin
promoted a reduction in microscopic damage score and apoptosis
(Table 3). These effects were biochemically accompanied by inhibi-
tion in MPO and AP activities (Table 4). The treatments with pred-
nisolone and sulphasalazine were not able to signiﬁcantly modify
any of the microscopic or macroscopic parameters evaluated. Bio-
chemically, both drugs were only able to counteract GSH content,
whereas sulphasalazine also inhibited colonic AP activity (Tables
4 and 5).3.3. Inhibition of cytokine production in cell cultures
The results obtained in these assays showed that 4-methylescu-
letin dose-dependently reduced the production of the different
cytokines studied (Fig. 3). In LPS-stimulated RAW264.7 macro-
phages, the coumarin derivative inhibited IL-1b release signiﬁ-
cantly at a concentration of 10 lM and achieved a complete
inhibition at a concentration of 50 lM. Similarly, the incubation
of 4-methylesculetin with IL-1b-stimulated Caco-2 cells reduced
the production of IL-8 at a concentration of 10 lM and obtained
a maximal inhibition of 70% at a concentration of 50 lM. Finally,
in concanavalin A-stimulated splenocytes, this compound/Kg) treatment on macroscopic damage score, colonic weight, incidence of diarrhoea,
)2 Diarrhoea (%)3 Adherence (%)3 Apoptosis/per crypt epithelial cells2
0a 0a 0.062 ± 0.004a
100b 83b 0.136 ± 0.015b
33a 33b 0.111 ± 0.019b
33a 0a 0.087 ± 0.012a
67bc 33a 0.089 ± 0.013a
e mean ± S.E.M.
ter differ p < 0.05.
Table 2
Effects of 4-methylesculetin (5 mg/Kg), prednisolone (2 mg/Kg) and sulphasalazine (50 mg/Kg) treatment on glutathione (GSH) content, myeloperoxidase (MPO) and alkaline
phosphatase (AP) activities and malondialdehyde content (MDA) in acute TNBS colitis.
Group GSH (nmol/g tissue) MPO (U/g tissue) AP (mU/mg protein) MDA (nmol/g tissue)
Non-colitic 1768 ± 90.63a 201 ± 26.20a 5.44 ± 0.45a 12.99 ± 1.83a
TNBS-control 1046 ± 51.92b 2246 ± 216.97b 16.62 ± 1.43b 20.07 ± 1.29b
4-Methylesculetin 1638 ± 443.41a 1590 ± 135.53c 11.41 ± 1.55c 18.00 ± 2.29ab
Prednisolone 1698 ± 84.31a 1441 ± 218.92c 9.96 ± 1.39a 15.58 ± 2.32ab
Sulphasalazine 1695 ± 98.90a 1550 ± 88.56c 10.91 ± 1.20c 16.57 ± 1.48ab
Data are expressed as mean ± S.E.M. Means without a common letter differ, p < 0.05.
Fig. 1. Effects of different treatments in TNBS rat colitis in biochemical parameters (acute protocol). This ﬁgure showed tumour necrosis factor alpha (TNF-alfa) and
interleucin 1-beta (IL-1beta) levels, matrix metalloproteinases 2 (MMP-2) and 9 (MMP-9) activities. (A) non-colitic; (B)TNBS-control; (C) 4-methylesculetin (5 mg/Kg), (D)
prednisolone (2 mg/Kg) and (E) sulphasalazine (50 mg/Kg). Data are expressed as mean ± S.E.M. MMP activity is expressed as densitometry as integrated optical density
(IOD). Value without a common letter differ p < 0.05.
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50 lM, resulting 65% and 100% inhibition, respectively, at the high-
est concentration assayed. The viability assays revealed that most
of the concentrations used were devoid of any signiﬁcant cytotoxic
effect, with the exception of RAW264.7, in which the concentration
of 100 lM of 4-methylesculetin showed an incidence of cytotoxic
effects of approximately 25%.
4. Discussion
This study conﬁrms the intestinal anti-inﬂammatory activity of
4-methylesculetin, at a dose of 5 mg/kg, in the TNBS model of rat
colitis. This natural compound showed similar efﬁcacy to that ob-
tained with either prednisolone (2 mg/kg) or sulphasalazine
(50 mg/kg), two of the main drugs currently used for the treatment
of human IBD. This beneﬁcial effect was observed following the
preventative dosing protocol used in the acute phase of experi-
mental colitis, as well as after a curative protocol in the chronic
phase.
In the chronic colitis with relapse model, the colonic damage
was initially characterised by a time-dependent recuperation of
inﬂammatory status, similar to that described previously in [11].Two weeks after the initial insult, the colonic segments still ap-
peared macroscopically ulcerated and inﬂamed. As expected, the
second administration of TNBS resulted in a reactivation of the co-
lonic damage in comparison with that observed in the control
colitic group without relapse.
The treatment with 4-methylesculetin, prednisolone or sul-
phasalazine showed an improvement of the intestinal inﬂamma-
tory process in all time points studied, either before or after the
second TNBS instillation. This was exhibited by a signiﬁcant de-
crease in the macroscopic damage score and by an inhibition in
colonic MPO activity, as this enzyme activity is a marker of neu-
trophil inﬁltration, which can be considered an index of inﬂam-
mation damage [24]. Colonic inﬂammation was also
characterised by an increase in AP activity, which has been attrib-
uted mainly to leucocyte activity [25]. AP enzyme activity has
been considered a sensitive biochemical marker of intestinal
inﬂammation [6,26,7] and its inhibition can be interpreted as a
result of the anti-inﬂammatory effect of a given compound. In
fact, 4-methylesculetin, prednisolone and sulphasalazine inhib-
ited AP activity in the ﬁrst week after TNBS instillation, while
4-methylesculetin and sulphasalazine also showed this activity
after the colitis relapse.
Fig. 2. Effects of different treatments in TNBS rat colits (acute protocol) in histological analyses. (A) Histological sections of colonic mucosa stained with haematoxylin and
eosin: (a) non-colitic; (b)TNBS-control; (c) 4-methylesculetin (5 mg/Kg), (d) prednisolone (2 mg/Kg) and (e) sulphasalazine (50 mg/Kg). (B) Colonic microscopic damage score.
Data are expressed as means ± SEM. ⁄p < 0.05;⁄⁄⁄p < 0.01 vs. TNBS control group.
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responsible for the tissue destruction. In this event, matrix
metalloproteinases (MMPs), a group of zinc-dependent endopep-
tidases, participate in extracellular matrix degradation and remod-
elling. Their enzymatic activity is regulated by tissue inhibitors of
the MMPs (TIMPs); however, under pathological situations, the in-
creased amount of active MMPs cannot be controlled by TIMPs,
resulting in extracellular matrix breakdown and tissue injury
[27]. As a result, drugs that are able to block the tissue damage-re-
lated MMPs or are able to increase the tissue protection-related
MMPs could be considered as good candidates for the treatment
of this disease. In IBD, the MMP gelatinases MMP-2 and MMP-9
has been described to display antagonistic functions [28]. Epithe-
lial-derived MMP-9 is an important mediator of tissue injury in
colitis in human, whereas MMP-2 protects the colon against tissue
damage and maintains gut barrier function [29]. It has been sug-
gested that the inhibition of intestinal MMP-9 activity may be ben-
eﬁcial in IBD [28]. In the present study, and in comparison with
non colitic rats, colonic MMP-9 activity was signiﬁcantly increased
in control colitic rats both in the acute and chronic phases of exper-
imental TNBS colitis, but not one week after colitic relapse. How-
ever, colonic MMP-2 activity was only signiﬁcantly inhibited one
week after the ﬁrst TNBS instillation. The administration of 4-
methylesculetin, prednisolone or sulphasalazine to colitic rats oncecolonic damage had been induced resulted in the inhibition of co-
lonic MMP-9 activity seven days after TNBS administration and
simultaneously maintained the protective activity of colonic
MMP-2.
TNF-a and IL-1b are clearly involved in the intestinal inﬂamma-
tory process by inducing the expression of different pro-inﬂamma-
tory proteins, including MMPs [30]. It is possible that the effect of
4-methylesculetin or prednisolone on MMP-9 activity is related, at
least in part, to the ability of these compounds to reduce IL-1b and
TNF-a colonic levels.
Because oxidative damage is involved in the pathogenesis of
IBD, antioxidant compounds have been studied for the treatment
of these intestinal conditions [31]. 4-methylesculetin, similar to
other coumarin derivatives, has been described to possess antiox-
idant and anti-inﬂammatory effects [32]. In a previous study, we
reported the beneﬁcial effect of 4-methylesculetin in TNBS-in-
duced colitis in rats. We concluded that its activity is likely related
to its antioxidant properties [13]. The results obtained in the pres-
ent study conﬁrm this observation because 4-methylesculetin im-
proved the biochemical markers of colonic oxidative stress, as
analysed by glutathione. Glutathione is a natural tripeptide that
displays antioxidant activity, and depletion of glutathione is
associated with experimental colitis [33] and MDA, the major
end-product of the oxidation of polyunsaturated fatty acids.
Table 3
Effects of 4-methylesculetin (5 mg/Kg), prednisolone (2 mg/Kg) and sulphasalazine (50 mg/Kg) treatment on macroscopic damage score, extension of lesion, microscopic damage
score and apoptosis in chronic with relapse of TNBS colitis.
Group Macroscopic damage score
(0–10)1
Colonic weight
(mg/cm)2
Microscopic damage score
(0–27)2
Apoptosis/per crypt epithelial cells
1 week
Non-colitic 0a 89.0 ± 7.42a 0a 0.079 ± 0.014a
TNBS-control 5.5 (5–7)b 147.5 ± 8.02b 13.0 (10–23)b 0.198 ± 0.021b
4-Methylesculetin 3.5 (3–5)c 138.3 ± 4.15b 10.5 (7–15)b 0.094 ± 0.02a
Prednisolone 2.0 (0–5)a 137.7 ± 8.39b 10.5 (7–14)b 0.109 ± 0.016a
Sulphasalazine 3.0 (2–6)c 139.1 ± 10.75b 12.0 (9–19)b 0.122 ± 0.016a
2 week
Non-colitic 0a 102.0 ± 3.89a 0a 0.070 ± 0.007ª
TNBS-control 3.0 (2–4)b 146.3 ± 9.59b 14.0 (10–17)b 0.273 ± 0.023b
4-Methylesculetin 2.0 (2–3)a 120.1 ± 5.56a 11.5 (6–18)b 0.132 ± 0.018c
Prednisolone 2.5 (0–3)a 134.9 ± 6.14b 11.0 (9–12)b 0.140 ± 0.017c
Sulphasalazine 3.0 (2–6)c 135.1 ± 2.72b 8.0 (4–13)b 0.161 ± 0.02c
3 week
Non-colitic 0a 97.9 ± 4.13a 0a 0.103 ± 0.009ª
TNBS-control with relapse 4.0 (2–4)b 138.1 ± 13.83b 14.0 (12–18)b 0.236 ± 0.021b
TNBS-control without relapse 2.0 (1–3)c 144.5 ± 3.30b 12.0 (9–17)b 0.117 ± 0.013ª
4-Methylesculetin 2.5 (1–3)c 151.8 ± 11.30b 7.5 (4–9)b 0.080 ± 0.008ª
Prednisolone 2.5 (2–3)c 171.5 ± 10.21b 13.0 (8–18)b 0.117 ± 0.01ª
Sulphasalazine 3.0 (2–5)c 171.0 ± 24.71b 12.0 (6–13)b 0.099 ± 0.011ª
1 Score data are expressed as the median (range).
2 Colonic weight data and apoptosis are expressed as the mean ± S.E.M. Value without a common letter differ, p < 0.05.
Table 4
Effects of 4-methylesculetin (5 mg/Kg), prednisolone (2 mg/Kg) and sulphasalazine (50 mg/Kg) treatment on glutathione (GSH) content, myeloperoxidase (MPO) and alkaline
phosphatase (AP) activities and malondialdehyde content (MDA) in chronic with relapse of TNBS colitis.
Group GSH (nmol/g tissue) MPO (U/g tissue) AP (mU/mg protein) MDA (nmol/g tissue)
1 week
Non-colitic 1500 ± 76.46a 109.7 ± 6.77a 7.23 ± 0.76a 12.18 ± 0.93a
TNBS-control 917 ± 26.21b 318.6 ± 51.67b 18.23 ± 4.18b 17.08 ± 1.11b
4-Methylesculetin 1016 ± 58.79c 177.5 ± 34.00a 9.96 ± 1.53a 12.99 ± 0.59a
Prednisolone 1223 ± 77.02c 128.4 ± 22.05a 6.38 ± 0.89a 12.56 ± 0.71a
Sulphasalazine 1268 ± 65.64a 154.6 ± 37.92a 7.28 ± 1.18a 17.47 ± 1.44bc
2 week
Non-colitic 2146 ± 78.71a 85.0 ± 7.70a 6.44 ± 0.95a 7.96 ± 0.55a
TNBS-control 1568 ± 123.04b 160.1 ± 24.96b 15.34 ± 2.12b 13.61 ± 1.97b
4-Methylesculetin 1715 ± 91.67b 121.7 ± 24.33ab 7.60 ± 0.44a 10.39 ± 1.13ab
Prednisolone 1875 ± 128.04b 114.7 ± 36.64ab 10.30 ± 1.20a 12.55 ± 0.98ab
Sulphasalazine 1841 ± 216.08b 100.9 ± 15.71ab 8.99 ± 1.01a 12.12 ± 1.22ab
3 week
Non-colitic 1741 ± 79.29a 95.0 ± 11.74a 6.81 ± 0.89ª 7.53 ± 0.81a
TNBS-control with relapse 1252 ± 74.08b 200.3 ± 25.54b 11.92 ± 1.69b 10.28 ± 0.79b
TNBS-control without relapse 1436 ± 76.84ab 154.4 ± 17.53ac 7.84 ± 0.82a 10.48 ± 1.07ab
4-Methylesculetin 1471 ± 11.83ab 164.0 ± 9.16c 6.60 ± 0.69a 9.51 ± 0.46ab
Prednisolone 1693 ± 111.90ac 167.6 ± 4.62bc 8.28 ± 0.83ab 12.45 ± 1.37b
Sulphasalazine 1676 ± 122.03ac 175.9 ± 46.47bc 7.58 ± 1.36a 11.92 ± 1.51b
Data are expressed as mean ± S.E.M. Means without a common letter differ, p < 0.05.
82 A. Witaicenis et al. / Chemico-Biological Interactions 195 (2012) 76–85Glutathione is frequently measured as indicator of the ‘‘in vivo’’
lipid peroxidation and oxidative stress. In addition, the reduction
in neutrophil inﬁltration, as detected by microscopic and biochem-
ical analyses, can also contribute to these protective effects on the
altered oxidative status in the inﬂamed colonic tissue.
It has been reported that the impairment in the epithelial bar-
rier function can account for the pathophysiology of IBD, leading
to a higher access of luminal agents to the intestinal tissue. Fur-
thermore, this impairment is also associated with a functional loss
of normal absorptive capacity and inappropriate secretion of intes-
tinal ﬂuid and electrolytes, thus promoting diarrhoea, abdominal
cramps, excessive gas, and bloating [34]. One of the processes that
has been proposed to be involved in the altered epithelial integrity
is the increase in intestinal epithelial cell apoptosis [35]. Inhibition
of cell apoptosis has been considered a symptomatic treatment op-tion for ill patients with severe diarrhoea [34]. This inhibitory ef-
fect on epithelial cell apoptosis may reduce villus atrophy and
epithelial destruction [36]. The present study reveals that 4-
methylesculetin, prednisolone and sulphasalazine reduced the
number of intestinal epithelial cell apoptotic events across all time
points studied during the chronic colitis with relapse. Different
mechanisms can be involved in this effect, and one of them could
be ascribed to the beneﬁcial effects exerted by these compounds
acting on the colonic oxidative status. Previously, it has been re-
ported that the excessive oxidative stress to which the intestinal
mucosa is subjected under inﬂammatory conditions might en-
hance epithelial apoptosis [37]. Therefore, it has been suggested
that IFN-c and TNF-a, the production of which is clearly increased
by the inﬁltrating immune-competent cells in these intestinal con-
ditions, contribute to epithelial cell apoptosis in the gut [34]. In the
Table 5
Effects of 4-methylesculetin (5 mg/Kg), prednisolone (2 mg/Kg) and sulphasalazine (50 mg/Kg) treatment on matrix metalloproteinase activity (MMP-9 and MMP-2), tumour
necrosis factor a (TNF-a) and interleukin 1b levels in chronic with relapse of TNBS colitis.
Group MMP-9 (IOD) MMP-2 (IOD) TNF-a (pg/mg protein) IL-1b (pg/mg protein)
1 week
Non-colitic 78.08 ± 18.54a 43.43 ± 15.82a 187.81 ± 14.53a 1370 ± 138.55a
TNBS-control 155.37 ± 31.41b 14.94 ± 5.40b 275.17 ± 21.18b 4412 ± 800.83b
4-Methylesculetin 60.25 ± 10.67a 33.82 ± 4.16ab 284.57 ± 15.54b 2055 ± 326.80a
Prednisolone 23.53 ± 3.37a 24.79 ± 4.38ab 170.82 ± 13.38a 1536 ± 291.58a
Sulphasalazine 70.17 ± 12.89a 34.03 ± 8.81ab 254.42 ± 17.80b 2289 ± 309.30a
2 week
Non-colitic 51.09 ± 3.46a 39.29 ± 5.11a 141.19 ± 16.60a 594 ± 117.60a
TNBS-control 104.29 ± 39.44b 78.63 ± 20.46a 174.81 ± 17.43a 1257 ± 225.45b
4-Methylesculetin 138.08 ± 33.13b 68.86 ± 35.01a 136.55 ± 22.59a 942 ± 126.73ab
Prednisolone 94.02 ± 26.99ab 41.58 ± 15.40a 141.55 ± 23.85a 1562 ± 244.74b
Sulphasalazine 124.96 ± 20.12b 79.46 ± 28.78a 153.45 ± 30.48a 1546 ± 226.46b
3 week
Non-colitic 70.06 ± 19.26a 37.66 ± 8.64a 65.28 ± 12.53ab 650 ± 85.93a
TNBS-control with relapse 102.09 ± 17.69a 32.95 ± 10.14a 89.73 ± 13.27ab 1045 ± 89.60bd
TNBS-control without relapse 103.58 ± 37.32a 41.92 ± 4.39a 59.00 ± 5.96a 570 ± 118.36ab
4-Methylesculetin 83.18 ± 12.76a 37.08 ± 7.12a 115.41 ± 25.70b 788 ± 149.21ab
Prednisolone 55.62 ± 6.98a 37.26 ± 5.97a 97.14 ± 10.41ab 2274 ± 133.66c
Sulphasalazine 84.21 ± 28.08a 47.99 ± 20.29a 116.24 ± 11.38b 1512 ± 164.80d
Data are expressed as mean ± S.E.M. MMP activity are expressed in densitometry as Integrated Optical Density (IOD).
Means without a common letter differ, p < 0.05.
Fig. 3. In vitro effects of 4-methylesculetin on cytokine production in different cell cultures. IL-1beta in RAW264.7 cells, IL-8 in Caco-2 cells and IL-2 and IFN-c in spleen cells.
(A) non stimulated cells; (B1) LPS + DMSO; (B2) IL-1 + DMSO; (B3) Concanavalin + DMSO; (C) 4-methylesculetin 1 lM; (D) 4-methylesculetin 10 lM; (E) 4-methylesculetin
50 lM and (F) 4-methylesculetin 100 lM. Results are expressed as mean ± S.E.M. ⁄p < 0.05, ⁄⁄p < 0.01 vs respective controls (B).
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INF-c can promote caspase-8 activation, resulting in oxidative
stress, the loss of membrane permeability and the occurrence of
an apoptotic effect [36,38]. For this reason, the effects that these
compounds can exert on cytokine production and release can also
account to their beneﬁcial effects in these intestinal conditions.
The ability of both prednisolone [39] and sulphasalazine [40] to re-
duce excess cytokine production is regulated through inhibition ofNF-jB activity. Of note, NF-jB is a redox-sensitive transcription
factor and is activated by oxidant stress in the inﬂamed intestinal
mucosa [41].
Since 4-methyl-esculetin was also able to inhibit cytokine pro-
duction, as well as prednisolone and sulphasalazine, it is possible
that its anti-inﬂammatory effect was also related to inhibition of
the NF-jB activation, but new studies are necessary to elucidate
this mechanism of action.
84 A. Witaicenis et al. / Chemico-Biological Interactions 195 (2012) 76–85Finally, the results obtained in the ‘‘in vitro’’ assays showed that
4-methylesculetin was also able to inhibit the production of IL-8,
IL-1b, IL-2 and IFN-c in a dose-dependent manner in different cell
types involved in the intestinal immune response, i.e., epithelial
cells (Caco2), macrophages (RAW264.7) and lymphocytes (mouse
splenocytes). This immunomodulatory effect can account for its
beneﬁcial effect during intestinal inﬂammation. Considering that
inhibition of IL-8, IL-1b, IL-2 and IFN-c production contributes with
in vivo anti-inﬂammatory effects produced by 4-methylesculetin, it
is plausible to suggest that effect was derived from absorption of 4-
methylesculetin. In fact, several studies shown that 4-methylescu-
letin structurally-related compounds as coumarin and coumarin
derivatives are prompted absorbed in small intestine, rapidly and
widely distributed into tissues to produce its pharmacological ef-
fects [42–45].
5. Conclusion
The intestinal anti-inﬂammatory activity shown by 4-methyle-
sculetin in the TNBS model of colitis can be ascribed to its ability to
reduce colonic oxidative stress and inhibit the production of pro-
inﬂammatory cytokines. Moreover, 4-methylesculetin also shows
a similar efﬁcacy to that demonstrated by prednisolone or sulpha-
salazine, two drugs currently used in the pharmacological treat-
ment of IBD in humans. Additionally, it is interesting to note that
the administration of 4-methylesculetin exerts both curative and
preventive effects, showing the latter effect both when the mucosa
is intact and when it is damaged and in the process of recovery.
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